Laboratorio de Regeneracion Cardiovascular, Instituto de Medicina Traslacional, Trasplante y Bioingenieria (IMETTYB), Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET) - Universidad Favaloro, Solis 453, Buenos Aires, Argentina.
Laboratorio de Ingenieria Genetica y Biologia Celular y Molecular, Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET) - Universidad Nacional de Quilmes (UNQ), Roque Saenz Pena 352, Bernal, Buenos Aires, Argentina.
Curr Drug Targets. 2019;20(2):241-254. doi: 10.2174/1389450119666180801122551.
Adult mammalian cardiomyocytes (CMs) exhibit limited proliferative capacity, as cell cycle activity leads to an increase in DNA content, but mitosis and cytokinesis are infrequent. This makes the heart highly inefficient in replacing with neoformed cardiomyocytes lost contractile cells as occurs in diseases such as myocardial infarction and dilated cardiomyopathy. Regenerative therapies based on the implant of stem cells of diverse origin do not warrant engraftment and electromechanical connection of the new cells with the resident ones, a fundamental condition to restore the physiology of the cardiac syncytium. Consequently, there is a growing interest in identifying factors playing relevant roles in the regulation of the CM cell cycle to be targeted in order to induce the resident cardiomyocytes to divide into daughter cells and thus achieve myocardial regeneration with preservation of physiologic syncytial performance. Despite the scientific progress achieved over the last decades, many questions remain unanswered, including how cardiomyocyte proliferation is regulated during heart development in gestation and neonatal life. This can reveal unknown cell cycle regulation mechanisms and molecules that may be manipulated to achieve cardiac self-regeneration. We hereby revise updated data on CM cell cycle regulation, participating molecules and pathways recently linked with the cell cycle, as well as experimental therapies involving them.
成年哺乳动物心肌细胞(CMs)增殖能力有限,因为细胞周期活动会导致 DNA 含量增加,但有丝分裂和胞质分裂很少发生。这使得心脏在替换因心肌梗死和扩张型心肌病等疾病而丢失的收缩细胞的新形成的心肌细胞方面效率低下。基于不同来源的干细胞植入的再生疗法不能保证新细胞与驻留细胞的植入和电机械连接,这是恢复心脏合胞体生理学的基本条件。因此,人们越来越感兴趣的是确定在调节 CM 细胞周期中起重要作用的因素,以便诱导驻留心肌细胞分裂为子细胞,从而实现心肌再生,同时保持生理合胞体性能。尽管在过去几十年中取得了科学进展,但仍有许多问题尚未得到解答,包括在妊娠和新生儿期心脏发育过程中如何调节心肌细胞增殖。这可能揭示未知的细胞周期调控机制和分子,这些机制和分子可能被操纵以实现心脏的自我再生。在此,我们回顾了最近与细胞周期相关的 CM 细胞周期调控、参与分子和途径的更新数据,以及涉及这些分子和途径的实验治疗方法。